| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 624* | 2022 |
| New discoveries in the pathogenesis and classification of vitiligo M Rodrigues, K Ezzedine, I Hamzavi, AG Pandya, JE Harris, ... Journal of the American Academy of Dermatology 77 (1), 1-13, 2017 | 494 | 2017 |
| CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo M Rashighi, P Agarwal, JM Richmond, TH Harris, K Dresser, MW Su, ... Science translational medicine 6 (223), 223ra23-223ra23, 2014 | 492 | 2014 |
| A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin JE Harris, TH Harris, W Weninger, EJ Wherry, CA Hunter, LA Turka Journal of Investigative Dermatology 132 (7), 1869-1876, 2012 | 431 | 2012 |
| Vitiligo: mechanisms of pathogenesis and treatment ML Frisoli, K Essien, JE Harris Annual review of immunology 38 (1), 621-648, 2020 | 419 | 2020 |
| Vitiligo pathogenesis and emerging treatments M Rashighi, JE Harris Dermatologic clinics 35 (2), 257-265, 2017 | 259 | 2017 |
| Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure LY Liu, JP Strassner, MA Refat, JE Harris, BA King Journal of the American Academy of Dermatology 77 (4), 675-682. e1, 2017 | 235 | 2017 |
| Current and emerging treatments for vitiligo M Rodrigues, K Ezzedine, I Hamzavi, AG Pandya, JE Harris, ... Journal of the American Academy of Dermatology 77 (1), 17-29, 2017 | 231 | 2017 |
| Innate immune mechanisms in vitiligo: danger from within JM Richmond, ML Frisoli, JE Harris Current opinion in immunology 25 (6), 676-682, 2013 | 231 | 2013 |
| Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial D Rosmarin, AG Pandya, M Lebwohl, P Grimes, I Hamzavi, AB Gottlieb, ... The Lancet 396 (10244), 110-120, 2020 | 230 | 2020 |
| Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) JE Harris, M Rashighi, N Nguyen, A Jabbari, G Ulerio, R Clynes, ... Journal of the American Academy of Dermatology 74 (2), 370-371, 2016 | 225 | 2016 |
| Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo JM Richmond, JP Strassner, L Zapata Jr, M Garg, RL Riding, MA Refat, ... Science translational medicine 10 (450), eaam7710, 2018 | 224 | 2018 |
| Immunology and skin in health and disease JM Richmond, JE Harris Cold Spring Harbor perspectives in medicine 4 (12), a015339, 2014 | 205 | 2014 |
| Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease JM Richmond, DS Bangari, KI Essien, SD Currimbhoy, JR Groom, ... Journal of Investigative Dermatology 137 (2), 350-358, 2017 | 192 | 2017 |
| Human Slug is a repressor that localizes to sites of active transcription K Hemavathy, SC Guru, J Harris, JD Chen, YT Ip Molecular and cellular biology 20 (14), 5087-5095, 2000 | 186 | 2000 |
| A network of high-mobility group box transcription factors programs innate interleukin-17 production N Malhotra, K Narayan, OH Cho, KE Sylvia, C Yin, H Melichar, ... Immunity 38 (4), 681-693, 2013 | 183 | 2013 |
| Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo D Rosmarin, T Passeron, AG Pandya, P Grimes, JE Harris, SR Desai, ... New England Journal of Medicine 387 (16), 1445-1455, 2022 | 168 | 2022 |
| Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells JE Harris, KD Bishop, NE Phillips, JP Mordes, DL Greiner, AA Rossini, ... The Journal of Immunology 173 (12), 7331-7338, 2004 | 161 | 2004 |
| Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo M Rashighi, JE Harris Annals of translational medicine 3 (21), 343, 2015 | 151 | 2015 |
| CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses SZ Chong, M Evrard, S Devi, J Chen, JY Lim, P See, Y Zhang, JM Adrover, ... Journal of Experimental Medicine 213 (11), 2293-2314, 2016 | 149 | 2016 |
Mehdi RashighiDepartment of Dermatology, University of Massachusetts Medical SchoolCorreu electrònic verificat a umassmed.edu